Skip to Content
scroll

(MRK US)

MRK US $85.40

20 MINUTE DELAYED

14 DAYS FREE ACCESS

Join Market Matters and get full access
to all our Opinion + Action

LEARN MORE

MRK US $85.40

20 MINUTE DELAYED

TODAY

0.11 %

1 YEAR RETURN

0.00%

VOLUME

567,322

DIV YIELD

0.00%

PE RATIO

13.15

52 WEEK RANGE

73.31

120.30

ANALYSIS

i

SHARE PRICE ACTIVITY
Last (Price)

85.40

Change

0.09 (0.11)

Bid / Ask

85.38 - 85.40

Volume

567,322

Turnover

25,149,921

Open

85.31

Day Range

85.01 - 85.57

VWAP

85.29

Prev Close

85.31

Last Trade

i

KEY INFORMATION
Sector

Shares Issued

NTA/Share

0.00

Last Dividend

3.24

Dividend Ex Date

15 SEP 2025

Dividend Pay Date

07 OCT 2025

i

BROKER CALLS

current

Mean

0.00

Target Price

0.00

i

CURRENT ()
Revenue

EBITDA

Profit

Earnings Per Share (EPS)

0

Dividend Per Share (DPS)

0

Yield %

3.80

Market Cap

0

Price to Earnings Ratio (P/E)

13.1503

i

TARGET PRICE FORECAST

i

ESTIMATES ()
Revenue

0.00

EBITDA

0.00

Profit

0.00

Earnings Per Share (EPS)

0.00

Dividend Per Share (DPS)

0.00

i

BROKER CONSENSUS RECOMMENDATION

BUY

SELL

Target Price

0.00

Lt Growth Rate

0.00

Recommendation ()

0.00
OPINION
image description

Business Summary

Merck & Co., Inc. is a global health care company. It offers health solutions through its prescription medicines, including biologic therapies, vaccines and animal health products. Its Pharmaceutical segment includes human health pharmaceuticals and vaccine products. Human health pharmaceutical products include therapeutic and preventive agents, sold by prescription, for the treatment of human disorders. Its Animal Health segment discovers, develops, manufactures and markets a range of veterinary pharmaceutical and vaccine products and health management solutions and services, for the prevention, treatment and control of disease in all livestock and companion animal species. Its lead candidate, MK-6070, is a T-cell engager targeting delta-like ligand 3, an inhibitory canonical Notch ligand. Its lead candidate, Restoret, is an investigational, potentially first-in-class tetravalent, tri-specific antibody that acts as an agonist of the Wingless-related integration site signaling pathway.

image description

Only available to Members

Take a free 14 day Market Matters trial – full access to all our reports, portfolios, positions, buy and sell recommendations. Access the latest views on the latest developments from professional money managers. It's free and no payment details are required
For membership options and pricing. Click here
Back to top